Washington University in St. Louis
Office of Technology Management

LEISHMANIA MAJOR MUTANT LACKING TOR3 GENE

Beverley, Stephen

Gill, John

T-019505

The creators used classical homologous recombination to remove both copies of the Leishmania major target of rapamycin (TOR3). This mutant was used to study TOR3's suitability as a potential drug candidate.

Da Silva, L. M., & Beverley, S. M. (2010). Expansion of the target of rapamycin (TOR) kinase family and function in Leishmania shows that TOR3 is required for acidocalcisome biogenesis and animal infectivity. *Proceedings of the National Academy of Sciences*, 107(26), 11965-11970.